Accetto Utilizziamo cookies per migliorare il nostro servizio e realizzare statistiche. Questa funzione puó essere disattivata cambiando la configurazione del browser. Continuando a navigare senza modificare questi parametri, consideriamo che l’uso di cookies sia accettato
Each lot is evaluated in culture with our LDLs to determine the degree of up regulation of LDL receptors. Lipoprotein Deficient Serum, bovine is used for blocking of interfering antibodies. It is evaluated in conjunction with low-density lipoprotein (LDL) to determine the degree of up regulation of low-density lipoprotein receptors.
The absence of lipoproteins allows for the undertaking of binding studies of lipoproteins to cells without the interference of the endogenous lipoproteins.
Prepared from calf serum. Store frozen (-20° C). Stable for 6-12 months if frozen.
The sequential centrifugation used to produce this human lipoprotein deficient serum removes 99% of the circulating lipoproteins (chylomicrons, VLDL, IDL, LDL HDL) and their associated lipids. What remains in the LPDS is mainly fatty acids bound to proteins such as albumin.This product is virtually lipoprotein free but not totally lipid free due to the presence of mainly the non-lipoprotein associated fatty acids. There may also be a very small of amount of sterols such as cholesterol bound to some proteins as well.
If there is a need for lipid free serum, then there are multiple protocols in the literature for the production of lipid free serum by the use of organic solvent extraction. Most of those protocols remove 97-99% of the cholesterol, triglycerides, and free fatty acids.
Salminen, A.; Åström, P.; Metso, J.; Soliymani, R.; Salo, T.; Jauhiainen, M.; Pussinen, P. J.; Sorsa, T. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity. FASEB J. 2015, 29 (4), 1435-1445.
Romagnuolo, R.; Scipione, C. A.; Boffa, M. B.; Marcovina, S. M.; Seidah, N. G.; Koschinsky, M. L. Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. J. Biol. Chem. 2015, 290 (18), 11649-11662.